Phase I Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma

Trial Profile

Phase I Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2013

At a glance

  • Drugs Temsirolimus (Primary) ; Sorafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2013 Changed from phase I/II to phase I trial, according to ClinicalTrials.gov.
    • 29 Feb 2012 Actual patient number (25) added as reported by ClinicalTrials.gov.
    • 29 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top